Novo Nordisk has announced an investment of approximately 750 million kroner (around $130 million) in new laboratories at the company's R&D campus in Måløv, Denmark.

Construction has started and the new facility, called the Diabetes Research House, will open in early 2016. It will be home to 350 employees and during the construction phase will generate more than 1,000 external jobs.

Mads Krogsgaard Thomsen, Novo’s chief science officer, said the new facility “will provide an environment for cutting-edge diabetes research within biotechnology and protein chemistry”. It comprises two laboratory wings, a middle building with office space and an auditorium seating 450 people.

The announcement came a day after Novo posted third-quarter net profits of 6.50 billion kroner, up 1%, while sales rose 8% to 22.25 billion kroner.

The firm's stable of modern insulin products, including Levemir (insulin detemir) contributed 10.64 billion kroner, an increase of 13%._ Sales of Victoza (liraglutide), Novo’s once-daily human glucagon-like peptide-1 analogue, rreached 3.44 billion kroner, up 21%.

As for Tresiba (insulin degludec), its new-generation, long-acting insulin, the firm was cautious about timelines for a refiling in the USA, saying it is waiting for more information from DEVOTE study, a cardiovascular outcomes trial demanded by the Food and Drug Administration which rejected Tresiba in February 2013.